Parabilis Medicines debuted on Nasdaq, achieving IPO haul surpassing Moderna's, while its product received FDA fast-track designation. Regeneron also acquired shares.
Steady: 1 in the last 7 days
Updated saturday
The latest in this situation
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Parabilis Medicines debuted on Nasdaq, achieving IPO haul surpassing Moderna's, while its product received FDA fast-track designation. Regeneron also acquired shares.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Parabilis reached alignment with the FDA on the dose and regimen of its drug.Sub-event
Parabilis IPO on Nasdaq, FDA fast-track for Zolucatetide, and corporate acquisitions including Moderna and Regeneron.1 source
Keep exploring
The entities involved
-
Nasdaq
American fully electronic stock exchange
-
Moderna
American biotechnology company
- FDA
-
Regeneron Pharmaceuticals
American pharmaceutical company
Nothing else this week.